United Therapeutics (NASDAQ:UTHR) PT Lowered to $280.00 at Bank of America

United Therapeutics (NASDAQ:UTHR) had its price target reduced by Bank of America from $303.00 to $280.00 in a research report released on Thursday morning, Benzinga reports. Bank of America currently has an underperform rating on the biotechnology company’s stock.

Several other research firms have also recently weighed in on UTHR. UBS Group lifted their target price on United Therapeutics from $300.00 to $370.00 and gave the company a buy rating in a research note on Monday, July 8th. Wells Fargo & Company lifted their target price on United Therapeutics from $325.00 to $350.00 and gave the company an overweight rating in a research note on Wednesday, June 12th. Morgan Stanley cut United Therapeutics from an overweight rating to an equal weight rating and lifted their target price for the company from $310.00 to $321.00 in a research note on Thursday, July 11th. Oppenheimer boosted their price target on United Therapeutics from $375.00 to $400.00 and gave the company an outperform rating in a research note on Thursday, May 2nd. Finally, HC Wainwright boosted their price target on United Therapeutics from $300.00 to $400.00 and gave the company a buy rating in a research note on Thursday, July 25th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of Moderate Buy and a consensus price target of $331.73.

United Therapeutics Stock Down 0.0 %

UTHR stock opened at $327.68 on Thursday. United Therapeutics has a twelve month low of $208.62 and a twelve month high of $343.98. The company has a market capitalization of $14.58 billion, a P/E ratio of 15.49, a PEG ratio of 1.06 and a beta of 0.55. The company has a current ratio of 4.35, a quick ratio of 3.64 and a debt-to-equity ratio of 0.02. The firm has a 50 day simple moving average of $308.33 and a 200-day simple moving average of $261.54.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 EPS for the quarter, missing the consensus estimate of $6.33 by ($0.48). United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The business had revenue of $714.90 million during the quarter, compared to the consensus estimate of $691.87 million. During the same quarter last year, the firm posted $5.24 earnings per share. United Therapeutics’s revenue was up 19.8% compared to the same quarter last year. On average, equities research analysts predict that United Therapeutics will post 25.4 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction that occurred on Tuesday, July 30th. The stock was sold at an average price of $337.40, for a total value of $1,214,640.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares in the company, valued at approximately $43,862. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, Director Martine A. Rothblatt sold 1,468 shares of the company’s stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $275.85, for a total value of $404,947.80. Following the completion of the transaction, the director now directly owns 130 shares in the company, valued at $35,860.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction on Tuesday, July 30th. The shares were sold at an average price of $337.40, for a total value of $1,214,640.00. Following the completion of the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at $43,862. The disclosure for this sale can be found here. In the last ninety days, insiders sold 95,044 shares of company stock worth $28,762,937. 12.50% of the stock is currently owned by insiders.

Institutional Trading of United Therapeutics

Large investors have recently bought and sold shares of the stock. Norges Bank bought a new stake in shares of United Therapeutics during the fourth quarter worth $100,519,000. Swedbank AB bought a new stake in shares of United Therapeutics during the first quarter worth $97,316,000. Nordea Investment Management AB grew its holdings in shares of United Therapeutics by 677.6% during the first quarter. Nordea Investment Management AB now owns 300,920 shares of the biotechnology company’s stock worth $72,422,000 after purchasing an additional 262,222 shares during the last quarter. Avidity Partners Management LP bought a new stake in shares of United Therapeutics during the fourth quarter worth $52,158,000. Finally, Canada Pension Plan Investment Board grew its holdings in shares of United Therapeutics by 567.2% during the first quarter. Canada Pension Plan Investment Board now owns 180,800 shares of the biotechnology company’s stock worth $41,533,000 after purchasing an additional 153,700 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.